 Print View Attached Docs: |
|||||||||
| 81995:CANCER ANTIGEN 27.29 | |||||||||
| Alias Names: | CA 27.29 / CA 27-29 / CA 27 29 | ||||||||
| Methodology: | Chemiluminescent Immunoassay (CLIA) | ||||||||
| Edit Date: | 11/5/2008 | ||||||||
| Performed: | Daily | ||||||||
| Released: | 24-48 hours after setup at PeaceHealth Laboratories’ reference lab. | ||||||||
| CPT Code: | 86300-90 | ||||||||
| Specimen Collection Details | |||||||||
| Collection: | One 7.5 mL serum separator tube (SST). | ||||||||
| Handling: | Allow to clot completely, centrifuge and separate serum from cells immediately. Pour into a plastic vial. Freeze. | ||||||||
| Stability: | 8 hours ambient, 48 hours refrigerated, or 3 months frozen. | ||||||||
| Standard Volume: | 1 mL serum | ||||||||
| Minimum Volume: | 0.5 mL serum | ||||||||
| Transport: | Frozen, on dry ice. | ||||||||
| Comments: | The CA 27.29 assay is intended for use as an aid in monitoring patients previously treated for stage II or III breast cancer. | ||||||||
| Rejection Criteria: | Plasma. . | ||||||||
| Reference Range: | |||||||||||||||||||
|
0-40 U/mL
|
|||||||||||||||||||
| Interpretive Data: Results obtained with different assay methods or kits cannot be used interchangeably. The CA 27.29 assay is intended for use as an aid in monitoring patients previously treated for Stage II or III breast cancer. Serial testing in patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. The test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment. Patients with confirmed breast carcinoma frequently have CA 27.29 levels within the reference interval. Elevated levels of CA 27.29 can be observed in patients with nonmalignant diseases. Therefore, this result cannot be interpreted as absolute evidence of the presence or absence of malignant disease and should always be used in conjunction with other diagnostic procedures, including information from the patient’s clinical evaluation. | |||||||||||||||||||